Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
The trial will compare the overall survival of perifosine plus capecitabine to placebo plus capecitabine in patients with refractory advanced colorectal cancer.
Colorectal Cancer
DRUG: Capecitabine|DRUG: Perifosine|DRUG: Placebo
Overall Survival, Monthly
Progression-free Survival, Every 6 weeks
The trial will compare the overall survival of perifosine plus capecitabine to placebo plus capecitabine in patients with refractory advanced colorectal cancer.